Zibotentan
- ZD4054
Cytostatic
Endothelin A receptor antagonist
Template: Infobox chemical / molecular formula search available
Zibotentan is a potential oral appliqued cytostatic drug for the treatment of hormone-refractory prostate cancer. Currently, it is in Phase 3 clinical trials.
Zibotentan developed by the British pharmaceutical company AstraZeneca. Medicinally the ethanolamine salt is used.
Pharmacology
Mechanism of Action
Zibotentan is a selective endothelin -A receptor antagonist. Its plasma half-life is 8 hours and the plasma protein binding of 73.8 %.